Published: July 23, 2024
Seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the postvaccination period Kenya remains to be elucidated. This study aimed determine seroprevalence anti-SARS-CoV-2 IgM and IgG evaluate vaccination uptake Nairobi, Kenya. was a cross-sectional conducted university setting. Serum levels were assayed using enzyme-linked immunosorbent assays. Mann–Whitney U test used for binary comparisons Kruskal–Wallis Test multigroup comparisons. Statistical significance set at p < 0.05. A total 189 participants enrolled (median age, 21 years; female, 50.8%). The 12.7% 87.8% IgG. Anti-SARS-CoV-2 titers higher among vaccinated vs. non-vaccinated individuals (p 0.001, = 2817.5), females males 0.024, 3616), those 6 months before >1 year earlier 0.002, H 12.359). hesitancy rate 43.4% underlying reasons included mistrust (22.4%), health concerns (19.7%), lack information (18.4%). Despite high IgG, vaccine necessitates community engagement education prior vaccines roll out.
Language: Английский